Durvalumab completion and re-administration after grade 2 radiation pneumonitis following concurrent chemoradiotherapy for unresectable stage III NSCLC: a single-center real-world study.
Aoki S, Ariyasu R, Kamima T, Sato Y, Tokumasu K, Anno W, Ogura Y, Kaneko M, Mun M, Ninomiya H, Nishio M, Yoshioka Y
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.